Skip to search formSkip to main contentSkip to account menu

Acecainide

Known as: Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)-, N Acetylprocainamide, N-acetylprocainamide 
A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.
National Institutes of Health

Related topics

Related topics

10 relations
Acecainide HydrochlorideIn Bloodagonistsanalogs & derivatives

Broader (1)

Anti-Arrhythmia Agents

Narrower (1)

desethyl-N-acetylprocainamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro.
We studied the effects of procainamide and N-acetylprocainamide (NAPA) in a conscious dog preparation of atrial flutter resulting… 
1987
1987
Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration.
Two patients with renal failure developed N-acetylprocainamide toxicity while receiving procainamide. Treatment consisted of… 
Highly Cited
1979
Highly Cited
1979
Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships.
The electrophysiologic effects of n-acetylprocainamide (NAPA) and procainamide (PA) were compared in 14 chloralose-anesthetized… 
Highly Cited
1979
Highly Cited
1979
Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy.
Excerpt We describe here the case of a patient with a procainamide-induced systemic lupus erythematosus-like reaction whose… 
1979
1979
Long‐term antiarrhythmic therapy with N‐acetylprocainamide
The effects of long‐term NAPA therapy were evaluated in 6 patients with chronic PVCs known to respond to this drug during a… 
Highly Cited
1977
Highly Cited
1977
Cumulation of N‐acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function
N‐Acetylprocainamide (NAPA) accumulated in the plasma of 6 cardiac patients with renal failure taking procainamide chronically… 
Highly Cited
1976
Highly Cited
1976
Artificial kidneys and clearance calculations
Clearance of solutes by artificial kidneys can be calculated using plasma flow and solute concentration, whole blood flow and… 
Highly Cited
1976
Highly Cited
1976
Antiarrhythmic efficacy of N‐acetylprocainamide in patients with premature ventricular contractions
Oral administration ofa 1.5‐gm dose of N‐acetylprocainamide (NAPA) to 9 patients with premature ventricular contractions (PVCs… 
Highly Cited
1975
Highly Cited
1975
Absolute bioavailability in man of N‐acetylprocainamide determined by a novel stable isotope method
Absorption of a single oral dose of N‐acetylprocainamide (NAPA) was studied in 3 normal subjects. Approximately 85% of the oral… 
Highly Cited
1974
Highly Cited
1974
N-Acetylprocainamide: An Active Metabolite of Procainamide 1
Summary N-Acetylprocainamide has been detected in the plasma samples of each of four patients receiving procainamide. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)